For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > BUSINESS
BUSINESS
- MTPC Subsidiary in Indonesia to Construct New Production Facility
September 10, 2013
- Kyowa Kirin to Establish New Research Center in Singapore, Conduct Joint Research with Local Research Institutes
September 10, 2013
- InCROM Subsidiary in Shanghai Set to Become Subsidiary of Chinese Pharma Giant, Aims for Business Expansion
September 10, 2013
- Wholesalers to Stress that Medical Institutions Will Not Have to Incur Any Losses Due to Consumption Tax Hike
September 10, 2013
- Novartis AG Takes Retraction of JIKEI Paper “Seriously”; Problems Partly Traced to “Limited Understanding” about Investigator-Led Trials
September 9, 2013
- Shionogi Launches Irtra Combination Tablets LD/HD
September 9, 2013
- Novartis Appoints Former AbbVie Exec to Lead Medical Scientific Affairs
September 6, 2013
- Otsuka Holdings President Has High Hopes for Rapid Lead Compound Discovery
September 6, 2013
- Otsuka to Buy US Biotech Firm Astex for US$886 Million
September 6, 2013
- Takeda Mulls Taking Stab at Generic Biz in Japan via ASKA
September 6, 2013
- General Logistics Companies Increasing Their Investment in Field of Drug Distribution; Opening More Specialized Warehouses
September 6, 2013
- Edoxaban Shows Non-Inferiority to Warfarin for VTE: Daiichi Sankyo
September 6, 2013
- Will Once-weekly Formulations and New Products Help GLP-1 Receptor Agonists Break Out of Their Slump?
September 6, 2013
- Teva Japan to Pursue High-Value-Added Generics, Eyes Partnerships with Japanese Companies: Chairman Krinsky
September 5, 2013
- Teva Pharma Japan Aims for the Top in Japan Generic Market by 2018: President
September 5, 2013
- Kyowa Kirin Ties Up with Ultragenyx for XLH Treatment KRN23
September 5, 2013
- ASKA to Launch Generic Biz Unit; Takeda’s Yonezawa to Take Helm
September 4, 2013
- Otsuka Paid 20 Billion Yen to Healthcare Professionals in FY2012, 5.4 Billion Yen for Information Provisioning
September 4, 2013
- Fuji Yakuhin, Sanwa Kagaku Launch Gout and Hyperuricemia Treatments Topiloric/Uriadec
September 4, 2013
- President or Head of General Medicine OK’ed Research Grants to 2 Universities: Novartis Exec
September 3, 2013
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…